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I
 
nnate recognition of bacterial products constitutes a
principal bulwark of our defenses against infection. In
vertebrates, innate mechanisms both instruct the adaptive
immune response and provide immediate protection from
infectious challenge. In all lower phyla, innate mechanisms
represent the totality of immune protection, attesting to
both the power and evolutionary precedence of these
mechanisms.
Although the workings of the adaptive immune system
may be traced in a satisfying way from generation of diver-
sity to ligation of surface immunoglobulin to clonal expan-
sion, a similarly complete and satisfying view of innate rec-
ognition is not in hand. Even the best characterized
example of innate recognition, the inflammatory response
to bacterial LPS (endotoxin), has a yawning gap in the steps
of its progression. Results of long anticipated work pub-
 
lished in a recent issue of 
 
Science
 
 (1) and in this issue of 
 
The
Journal of Experimental Medicine
 
 (2) have now identified a
molecule with a privileged position in innate recognition
and the potential to fill this major gap.
 
The Missing Pieces in the Innate Immunity Puzzle.
 
Work
on innate recognition of LPS has generated information
from two polar starting points. The first has followed LPS
and its binding partners during the initial interaction with
cells. This work has shown that LPS is first acted on by LPS
binding protein (LBP), a plasma lipid transfer protein that
moves LPS monomers from aggregates or bacterial mem-
branes to a binding site on CD14 (3, 4). CD14, a protein
expressed both in plasma and as a glycosylphosphatidylino-
sitol (GPI)-linked protein on the surface of leukocytes,
then transfers LPS monomers into the plasma membrane of
 
cells (references 3 and 5, and Vasselon, T., E. Hailman, R.
Thieringer, and P.A. Detmers, manuscript submitted for
publication). LPS moves in turn to the Golgi apparatus via
an as yet undefined vesicular pathway (reference 6 and Thie-
blemont, N., and S.D. Wright, manuscript submitted for
publication). The goal of this approach has been to identify
the binding partner or “receptor” that discriminates LPS
from host lipids and transduces signals across the mem-
brane—but this goal has remained elusive: neither LBP nor
CD14 has the binding specificity to discriminate LPS from
host lipids (3, 7), and experiments to identify new binding
partners for LPS in cells have been uniformly frustrating.
The second line of work began with gene expression in
the nucleus and has worked backward toward determining
the agents that initiate new transcription. LPS causes dra-
matic transcriptional regulation of a wide range of proinflam-
matory genes including TNF, IL-1, IL-8, IL-6, ICAM-1,
E-selectin, tissue factor, and many more. LPS-dependent ac-
tivation of these genes has been shown to be controlled by
 
the transcription factors, nuclear factor (NF)-
 
k
 
B and AP-1.
These transcription factors are in turn controlled by kinases
that are rapidly activated by LPS (8, 9). For this approach as
well, the still unmet goal is to identify the receptor that dis-
criminates LPS from host lipids at the membrane and ini-
tiates the kinase cascade. The new work reviewed here fo-
cuses on the potential interface between the molecules
defined by these two lines of investigation, and this article
will focus on the extent to which a connection can be made.
 
Toll Proteins and the Response to LPS.
 
Both recent stud-
ies discussed here (1, 2) examine the molecular defect in
well-characterized mouse strains (C3H/HeJ and C57BL10/
ScCr) that exhibit impaired ability to respond to LPS.
Work on these mice over the past 20 yr has shown that hy-
poresponsiveness to LPS maps to a single autosomal locus
(
 
lps
 
), and impaired responses can be documented both in
whole animals and in cells taken from the animals (10). The
consequence of this hyporesponsiveness is a dramatically
 
enhanced susceptibility of 
 
lps
 
d
 
 animals to challenge with
Gram-negative pathogens. Importantly, the animals respond
normally to Gram-positive challenge and do not have other
health defects. This phenotype corresponds precisely with
that expected of a defect in innate recognition of LPS. It is
 
fair to say that studies of 
 
lps
 
d
 
 animals did not merely “confirm
expectations” about innate immunity. Rather, they showed
for the first time that a functional innate mechanism for de-
tecting particular microorganisms actually exists in mammals,
that the range of microorganisms detected by this system is
roughly defined as “Gram-negative bacteria,” and that this
mechanism plays an important role in resistance to infection.
These studies have propelled research on LPS recognition as
a paradigm of innate immunity. The identification of the ge-
netic defect in 
 
lps
 
d
 
 
 
mice has long been a holy grail, with the
potential to reveal a protein at the heart of innate immunity,
and that protein is now in hand.
Both Poltorak et al. (1) and Qureshi et al. (2) performed
extensive genetic mapping to narrow the position of the 
 
lps
 
locus to a region of chromosome 4, both assembled the tar-
get region on YACs and BACs, and both sought candidate
genes on the basis of sequence and expression. However,
for both groups, the most important clue came not from
mapping but from studies in 
 
Drosophila
 
 which identified the
Toll protein as a key player in the response to fungal infec-
tion (11). Several mammalian homologues of Toll have
been discovered (see below), and recent studies had shown
that TLR4 (Toll-like receptor 4, also known as hToll) can 
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initiate signaling steps similar to those seen in response to
LPS (12). Both Poltorak et al. and Qureshi et al. found
TLR4 in the target region of chromosome 4, and both
groups identified a missense mutation in the cytoplasmic
domain of TLR4 in C3H/HeJ. Importantly, an indepen-
dent mutation at the 
 
lps
 
 locus in the C57BL10/ScCr strain
resulted in the absence of TLR4 message, offering a strong
confirmation of the correct identification of TLR4 as the
defective protein resulting in the 
 
lps
 
d
 
 
 
phenotype. The for-
mal proof that TLR4 accounts for impaired responses to
LPS still must come from reconstitution of the defect with
authentic sequence, but the data in hand provide fair assur-
ance that the identification is correct.
 
The Toll Family and Signal Transduction.
 
Toll is a trans-
membrane protein that was discovered as a necessary player
in the establishment of dorsal-ventral polarity in 
 
Drosophila
 
embryos (13). The cytoplasmic domain of Toll bears signif-
icant homology with the cytoplasmic domain of the IL-1
receptor, and Toll signals transcriptional changes in 
 
Drosoph-
ila
 
 through a cascade of proteins with remarkable similarity
to those used by the IL-1 receptor:
 
IL-1R 
 
®
 
 MyD88 
 
®
 
 IRAK
 
®
 
 I
 
k
 
B 
 
®
 
 NF-
 
k
 
B 
 
®
 
 gene expression
Toll
 
®
 
Tube
 
®
 
 Pelle
 
®
 
 Cactus 
 
®
 
 Dorsal 
 
®
 
 gene expression.
 
In addition to its role in embryogenesis, Toll also plays an
important role in antifungal defenses of flies, being neces-
sary for the strong upregulation of drosomycin in response
to fungal infection (11).
Recent observations from Medzhitov et al. (12) indicate
that a human homologue of Toll (TLR4) can be an effective
signaling molecule in mammalian cells. A constitutively ac-
tive TLR4 construct drives NF-
 
k
 
B activation, AP-1 activa-
tion, and cytokine production in transfected cells (12). Addi-
tional data show that, like the IL-1R, TLR4 uses MyD88
and IRAK to activate NF-
 
k 
 
B (14, 15). As described above,
NF-
 
k
 
B and AP-1 activation are key players in responses to
LPS, and these data suggest that activation of a receptor such
as TLR4 may be sufficient to explain the transcriptional re-
sponses to LPS. Together with the observation that the 
 
lps
 
d
 
phenotype derives from defective TLR4, we may conclude
that at least under some conditions TLR4 is necessary and
sufficient for responses to LPS. These findings now extend
our understanding of the steps in LPS signal transduction
from the nucleus all the way to the membrane.
Additional data suggest that, as expected with any im-
portant physiological function, redundancy exists with re-
spect to LPS signaling. Although 
 
lps
 
d
 
 
 
mice are hyporespon-
sive to LPS, they are not unresponsive, and LPS-dependent
gene transcription will occur if a very large dose of LPS is
administered (10). Moreover, the sensitivity of 
 
lps
 
d
 
 
 
cells and
animals may be restored by activation with IFN-
 
g 
 
(16, 17),
and cells from C3H/HeJ mice are nearly as sensitive as their
normal counterparts when stimulated with certain types of
LPS (e.g., 
 
Porphyromonas gingivalis
 
 LPS) (18). These obser-
vations suggest that proteins other than TLR4 may replace
the function of TLR4 in signal transduction for responses
to LPS.
The best candidates for backing up TLR4 are other
 
members of the Toll family. In 
 
Drosophila
 
, a homologue of
Toll known as “18 wheeler”
 
 
 
also plays a role in host defense
but serves primarily in recognition of bacterial rather than
fungal pathogens (19). In humans, five homologues of Toll
have been described by three groups (12, 20, 21). Impor-
tantly, transfection of cell lines with TLR2 confers on them
the ability to respond to LPS with activation of NF-
 
k
 
B (22,
23), thus directly suggesting that TLR2 may serve in place
of TLR4. It is interesting to note that Kirschning et al. (23)
examined not only TLR2 but also TLR4. Contrary to the
prediction from the 
 
lps
 
d
 
 mice, transfection of TLR4 led to
constitutive activation of NF-
 
k
 
B with no enhancement
upon addition of LPS. The reasons for this discrepancy are
not clear but could derive from the presence of the addi-
tional “Flag” sequence in the TLR4 construct or the re-
quirement for a factor or subunit not present in the recipi-
ent cells. It is clear that a great deal of work needs to be
done to fully describe the cell distribution, regulation, and
contribution of individual members of the Toll family to
responses to LPS and other microbial products.
 
Toll and Discrimination of LPS from Host Lipids.
 
As outlined
above, TLR4 appears to be an early and necessary part of the
signal transduction machinery linking LPS with gene expres-
sion. Since TLR4 is a transmembrane protein, we may now
ask the most important question: is TLR4 the critical “LPS
receptor” that discriminates LPS from host lipids and initiates
signaling? Is it the last piece in the puzzle, the “T cell recep-
tor of endotoxin biology?” Use of Occam’s razor makes this
the obvious suggestion. On the other hand, any casual in-
spection of a diagram of signal transduction will reveal that
nature has made scant use of Occam’s razor in this area, and
the remainder of this commentary will address the known
and possible links between LPS and TLR4.
The extracellular domain of TLR4 contains 22 copies of
a leucine rich repeat (LRR) motif. The best characterized
binding partner of LPS, CD14, contains 10 copies of the
LRR motif. Despite this marvelous similarity, it is unlikely
that the LRRs of TLR4 represent an LPS binding site.
Mapping studies with CD14 have revealed that 7 out of the
10 LRRs can be deleted without affecting LPS binding
(24), and additional mapping studies have defined residues
outside the LRR region of CD14 that are clearly necessary
for LPS binding (25). Yang et al. (22) have suggested that
LPS may bind directly to TLR2. However, the affinity and
stoichiometry observed were so low as to eliminate any bi-
ological significance of this phenomenon, and at present
there is no strong evidence for a direct, meaningful interac-
tion of LPS with any member of the Toll family. An alter-
native to direct binding of LPS is an interaction of TLR4
with CD14. Although conceptually attractive, work with
CD14 has failed to uncover a binding partner in cells. De-
spite use of probes of extremely high sensitivity, it has not
been possible to measure binding of CD14 (26) or CD14-
LPS complexes (Vasselon, T., and R. Thieringer, unpub-
lished observations) to LPS-responsive cells.
A key to understanding how LPS might interact with
TLR4 (or any other adapter protein) comes from a consid-
eration of the form and location of the LPS during recogni- 
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tion. LPS is an amphiphile that will incorporate into lipid
bilayers. Indeed, CD14 readily donates LPS to liposomes,
lipoprotein particles, and the membranes of responsive cells
(references 5, 27, and 28, and Vasselon, T., E. Hailman, R.
Thieringer, and P.A. Detmers, manuscript submitted for
publication). Two lines of evidence suggest that LPS signals
responses not as a monomer but as a component of the
lipid bilayer. Scientists at Eisai Pharmaceuticals have syn-
thesized an LPS homologue, E5531, that acts as a powerful
antagonist of LPS action in cells and animals (29). Inversion
of all 13 chiral centers of E5531 yields a mirror image, and
this mirror image compound shows equal ability to antago-
nize LPS action (Christ, W.J. 1998. Advances in synthetic
LPS antagonists. Oral presentation at Fifth Conference of
the International Endotoxin Society, Santa Fe, NM). This
finding argues that LPS is not recognized in the stereospe-
cific fashion expected of stoichiometric interactions with
proteins. An alternative is that the colligative properties,
which are identical in enantiomers, may be key to the bio-
logical action of E5531 and LPS. This possibility is sug-
gested by the finding that another LPS analogue (from
 
Rhodobacter sphaeroides
 
) may be converted from an antago-
nist to an agonist by simultaneous addition of the mem-
brane-active agent, chlorpromazine (30). From these con-
siderations, we are directed to seek recognition proteins
that either sense LPS in a bilayer or that sense the proper-
ties of a bilayer containing LPS.
There is only one well-characterized precedent in which
membrane composition is sensed and relayed to gene ex-
pression. The concentration of cholesterol in membranes of
the endoplasmic reticulum is gauged by a set of proteins
that control transcription of the genes for cholesterol syn-
thesis and uptake and which thereby affect cholesterol ho-
meostasis at the cellular level (for review see reference 31).
In brief, low levels of cholesterol in the endoplasmic retic-
ulum are thought to be sensed by a multispan protein
known as SCAP. SCAP controls the action of a transmem-
brane protease (S1P). Interestingly, the proteolytic domain
of S1P is lumenally disposed (32), and its substrate is an in-
tralumenal loop of SREBP (sterol response element bind-
ing protein), a transcription factor. Cleavage of the SREBP
by S1P in turn enables a second cleavage on the cytoplas-
mic face of SREBP, and this cut liberates a fragment of
SREBP that acts as a transcription factor. For the purposes
of this discussion, the message I wish to take from this di-
version is that membrane composition can be sensed and
that, at least for cholesterol, the actuation device is a pro-
tease cascade that starts in the lumen of an intracellular ves-
icle. For completeness, it should be added that just as Toll
is involved in dorsal-ventral polarity in 
 
Drosophila
 
, other
genes known as 
 
hedgehog
 
 and 
 
patched
 
 are involved in estab-
lishing anterior-posterior polarity (33). 
 
Hedgehog
 
 encodes a
 
protein covalently derivatized with cholesterol, and 
 
patched
 
encodes a homologue of SCAP.
Several observations suggest that LPS may activate a pro-
tease cascade and that a protease cascade may play a role in ac-
tivation of receptors such as Toll. In 
 
Drosophila
 
, the ligand for
Toll that drives dorsal-ventral polarity is a proteolytic frag-
ment of the protein, spätzle. Spätzle
 
 
 
is cleaved by the pro-
tease, easter, and easter in turn is activated by another protease
known as snake (13). It is also well known that LPS can ini-
tiate a protease cascade that leads to clotting in arthropods,
and the familiar 
 
Limulus
 
 amebocyte lysate (LAL) assay for LPS
exploits this cascade. Recent studies indicate a high similarity
between the LPS-induced clotting cascade and the Toll
cascade (34). Snake and easter are homologues of the 
 
Limulus
 
proteases factor B and proclotting enzyme, respectively. The
final step of the LAL reaction involves cleavage of coagulo-
gen. As its name implies, coagulogen forms a fibrin-like clot
but recent crystal structure analysis (35) has revealed that, in
addition, coagulogen contains a cysteine knot fold also found
in spätzle, NGF, TGF-
 
b
 
, and other signaling molecules. It is
thus a reasonable possibility that LPS may initiate a protease
cascade to generate ligands for receptors such as Toll.
Could a protease cascade function in recognition of LPS
in mammalian cells? The only soluble factors needed for re-
sponses of mammalian cells to LPS in vitro are LBP and
CD14, arguing against a role for a plasma-borne protease
cascade. An alternative source of a cascade is the cell itself
with the proteases being membrane bound. Many trans-
membrane proteases have been characterized and are
known to function in sensing cholesterol concentration
(described above), processing of 
 
notch
 
 (36), and maturation
of signaling proteins such as insulin (37). Additionally, since
LPS is rapidly internalized and carried to the Golgi, soluble
components may exist in sufficient concentration in this
organelle. It is worth noting that like LPS, ceramide is also
transported rapidly to the Golgi (38) and 
 
lps
 
d
 
 cells fail to re-
spond to ceramide (39). Membrane-bound proteases such
as furin are known to be concentrated in the Golgi (37),
certain genes that act upstream of Toll (pipe and windbeut-
lel) are found in the Golgi (13), and the IL-1R has been re-
ported to traffic to the Golgi after ligation (40).
In conclusion, the new work describing a role for TLR4
in responses to LPS clearly adds a piece to the puzzle of
LPS responsiveness and innate immunity. How important
is this piece? TLR4 clearly contributes a new part of the
signal transduction cascade but it is not clear that TLR4
contributes to the most vexing problem in innate immu-
nity: how do cells discriminate LPS or other microbial
molecules from similar structures in the environment?
Work in the next year should clarify this issue, but this au-
thor’s view is that TLR4 may be well downstream of the
step or steps discriminating host from pathogen.
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